The answer is 17 years, what is the question: understanding time lags in translational research.

Morris ZS, Wooding S, Grant J. · 2011

Read The answer is 17 years, what is the question: understanding time lags in translational research. by Morris ZS, Wooding S, Grant J. (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3241518.txt.

Introduction

Zoë Morris, Steven Wooding, and Jonathan Grant examined a famous claim about medical research. The claim says findings take seventeen years to reach patients. Their paper appeared in the Journal of the Royal Society of Medicine in 2011. They reviewed studies that actually measured time lags in turning health research into interventions, expecting to learn where the delays sit.

Only twenty-three papers qualified, and they were barely comparable: each measured different things, in different ways, at different points in the pipeline. The authors conclude that knowledge of time lags is too patchy to guide those who fund research or move it into practice, effectively blindfolding investment decisions. Before lags can be shortened, the field needs shared models, definitions, and measures that can be applied consistently in practice.

Catalog record

CREATORMorris ZS, Wooding S, Grant J.
YEAR2011
COLLECTIONPAPERS
FORMATTXT
FILE SIZE29 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3241518

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

The answer is 17 years, what is the question: understanding time lags in translational research By Zoë Slote Morris, Steven Wooding, Jonathan Grant Published in: Journal of the Royal Society of Medicine DOI: 10.1258/jrsm.2011.110180 ABSTRACT Abstract This study aimed to review the literature describing and quantifying time lags in the health research translation process. Papers were included in the review if they quantified time lags in the development of health interventions. The study identified 23 papers. Few were comparable as different studies use different measures, of different things, at different time points. We concluded that the current state of knowledge of time lags is of limited use to those responsible for R&D and knowledge transfer who face difficulties in knowing what they should or can do to reduce time lags. This effectively ‘blindfolds’ investment decisions and risks wasting effort. The study concludes that understanding lags first requires agreeing models, definitions and measures, which can be applied in practice. A second task would be to develop a process by which to gather these data. INTRODUCTION Timely realization of the benefits of expensive medical research is an international concern attracting considerable policy effort around ‘translation’.1,2 Policy interventions to improve translation respond to a vast empirical literature on the difficulties of getting research across research phases and into practice.3–11 Both literature and policy tend to assume that speedy translation of research into practice is a good thing. Delays are seen as a waste of scarce resources and a sacrifice of potential patient benefit.12 Although some lag will be necessary to ensure the safety and efficacy of new interventions or advances, in essence we should aim to optimize lags. One recent study (of which JG and SW were co-authors) estimating the economic benefit of cardiovascular disease (CVD) research in the UK between 1975 and 2005, found an internal rate of return (IRR) of CVD research of 39%.13 In other words, a £1.00 investment in public/charitable CVD research produced a stream of benefits equivalent to earning £0.39 per year in perpetuity. Of this, 9% was attributable to the benefit from health improvements, which is the focus of this paper. (The remaining 30% arise from ‘spillovers’ benefiting the wider economy.) This level of benefit was calculated using an estimated lag of 17 years. Varying the lag time from 10 to 25 years produced rates of return of 13% and 6%, respectively, illustrating that shortening the lag between bench and bedside improves the overall benefit of cardiovascular research. What is notable is that all the above calculations depended upon an estimated time lag; estimated because, despite longstanding concerns about them,14 time lags in health research are little understood. It is frequently stated that it takes an average of 17 years for research evidence to reach clinical practice.1,3,15 Balas and Bohen,16 Grant17 and Wratschko18 all estimated a time lag of 17 years measuring different points of the process. Such convergence around an ‘average’ time lag of 17 years hides complexities that are relevant to policy and practice which would benefit from greater understanding.13 Despite longstanding concerns about delays in getting research into practice, the literature on time lags seems surprisingly under-developed. To help address this gap, this paper aims to synthesize existing knowledge and to offer a conceptual model that can be used to standardize measurement and thus help to quantify lags in future. This would allow efforts to reduce lags to be focused on areas of particular concern or value, or on areas where interventions might be expected to have best effect. It would also provide the potential for evaluating the cost-effectiveness of translation interventions if their impact on lags can be measured. The aim was to overlay empirical lag data onto the conceptual model of translational research to provide an overview of estimated time lags and where they occur. The first part of the paper explores conceptual models of the translation pipeline in order to provide context. The second part of the paper presents a review of the literature on time lags to present current estimates and issues. This leads to a discussion on the current state of understanding about time lags and considers the implications for future practice and policy. METHODS For the first part of the study we identified literature that described conceptual models of translation. Our search was not intended to be exhaustive, but included key policy documents and searches of Google Scholar, Web of Science, PubMed and EBSCO. Key words used to retrieve relevant studies included ‘valley of death’, ‘bench to bedside’, ‘translational research’ and ‘commercialisation’. In general, ‘grey’ literature was not included in the search, but the HERG study19 was included because of the authors' involvement in it. The models in the literature found by these methods were summarized into a simple conceptual model. For the second part of the study we reviewed the literature on time lags in health research. We used the same methods and literature as for the first part but included additional search terms such as ‘time lag’ or ‘time-lag’, ‘delays’, ‘time factors’ (PubMed MESH term) and ‘publication bias’. We found a formal search yielded few relevant papers so combined a number of approaches to increase our confidence that relevant papers had been identified. We undertook backward and forward citation tracking to identify related work and used searches within targeted journals – e.g. Scientometrics and Journal of Translational Medicine. To analyse the lag data, we used a data extraction template with the following fields: start and end dates for measurement period, range, mean, median, dates used, topic, country of study. In addition, the start point and endpoint of the time lag measured in each study were mapped onto specific stages in the conceptual model developed in the first part of the study. FINDINGS Conceptualising translational research Understanding time lags requires a conceptual model of how research in science is converted to patient benefit so that the durations of activities and waits can be measured. This process of conversion of basic science to patient benefit is often called ‘translation’.1,2,18,20–22 Woolf has argued that ‘translation research means different things to different people’23 and this is reflected in the various models and definitions found in the literature. However, as translational research also ‘seems important to almost everyone’23 there would seem to be benefit in trying to unify models and definitions. We have attempted to synthesize these models to identify key features of the translation process and to offer a tentative unified model. This was intended to help stakeholders agree a model which could be used to support future data gathering and better guide policy-making. We recognized that drug development, public health, devices and broader aspects of healthcare practice will vary in nature. The translation process is summarized briefly in Figure 1. Clearly this model can be critiqued for being linear and we acknowledge the considerable literature that challenges this notion and accept that research translation is a messy, iterative and complex process (see Balaconi et al. for a good review of the liner models critiques and their partial rebuttal24). At the same time, we would argue that for the purposes of understanding and conceptualising time lags the model is appropriate in showing common steps found in the literature. [Figure: A

Read the complete text